ConKay Medical Systems is a 2023 Rosenman Innovator and medtech start-up company. Conkay’s innovative technology helps treat patients suffering from valvular regurgitation, and has closed an oversubscribed $1.8M seed round to support the company growth and development of its one-size fits all annular repair catheter system.
From the press release:
PLEASANTON, Calif.–(BUSINESS WIRE)–ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
Albert Yuan, Founder and CEO of ConKay Medical, shared, “Millions of Tricuspid Regurgitation patients worldwide are currently left with no medical options and at ConKay, our mission is to help patients live longer lives with their loved ones. We are grateful to our investors for their trust and support in helping us achieve this goal.”
There are more than 70 million people worldwide with Tricuspid Regurgitation. Current devices, including those in trials, have major limitations preventing patients with severe Tricuspid regurgitation from receiving treatment. ConKay’s unique catheter is completely adjustable and tackles all the current limitations, including avoiding pacemaker leads. Without the need to open a patient’s chest, the device mimics open heart surgery by leaving a minimal implant around the annulus of the valve.
The company anticipates raising its next round of financing in the 2nd quarter of 2024 to support First-in-Human testing.